Leverage is minimal with total debt of roughly $76M to $88M and a debt-to-equity ratio falling from 0.13 to 0.05, as equity growth from external capital raises diluted rather than repaid obligations.
Kymera Therapeutics, Inc. (KYMR) balance sheet — 8-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Total Current Assets | 998.59M | 871.21M | 510.27M | 405.32M | 419.42M | 451.27M | 302.34M | 92.84M | 41.79M |
| Cash & Short-Term Investments | 971.21M | 848.28M | 488.74M | 374.88M | 407.17M | 442.42M | 296.2M | 91.96M | 41.26M |
| Cash Only | 373.37M | 357.01M | 120.26M | 109.97M | 68.39M | 47.98M | 31M | 76.02M | 41.26M |
| Short-Term Investments | 597.84M | 491.26M | 368.49M | 264.92M | 338.77M | 394.44M | 265.2M | 15.94M | 0 |
| Accounts Receivable | 0 | 0 | 947K | 18.76M | 2.54M | 135K | 1.43M | 0 | 148K |
| Days Sales Outstanding | 17.85 | - | 7.34 | 87.14 | 19.78 | 0.68 | 15.37 | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 6.97 | - | - | - | - | - | - | - | - |
| Other Current Assets | 27.38M | 22.94M | 20.58M | 11.67M | 9.71M | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 768.68M | 871.6M | 467.77M | 170.44M | 183.72M | 154.63M | 184.84M | 23.86M | 2.44M |
| Property, Plant & Equipment | 78.69M | 85.53M | 97.86M | 101.08M | 22.24M | 21.31M | 20.69M | 22.08M | 2.24M |
| Fixed Asset Turnover | 1.24x | 0.46x | 0.48x | 0.78x | 2.11x | 3.42x | 1.65x | 0.13x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 3.16B | 776.96M | 362.16M | 61.43M | 152.33M | 125.19M | 162.53M | 0 | 199K |
| Other Non-Current Assets | 15.32M | 9.11M | 7.74M | 7.93M | 9.15M | 8.14M | 1.62M | 1.77M | 0 |
| Total Assets | 1.77B | 1.74B | 978.03M | 575.76M | 603.13M | 605.9M | 487.18M | 116.7M | 44.23M |
| Asset Turnover | 0.06x | 0.02x | 0.05x | 0.14x | 0.08x | 0.12x | 0.07x | 0.03x | - |
| Asset Growth % | 265.78% | 78.2% | 69.87% | -4.54% | -0.46% | 24.37% | 317.45% | 163.85% | - |
| Total Current Liabilities | 89.72M | 83.21M | 67.77M | 85.69M | 71.34M | 92.54M | 110.62M | 34.57M | 4.69M |
| Accounts Payable | 11.92M | 4.01M | 5.99M | 7.08M | 4.33M | 4M | 4.37M | 3.28M | 2.06M |
| Days Payables Outstanding | -45.15 | - | - | - | - | - | - | 1.45K | 3.66K |
| Short-Term Debt | 0 | 13.76M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 22.93M | 22.93M | 13.58M | 37.88M | 35.26M | 61.74M | 92.55M | 23.35M | 2.32M |
| Other Current Liabilities | 905K | 24.2M | 223K | 23.16M | 303K | 228K | 106K | 0 | 1.31M |
| Current Ratio | 11.13x | 10.47x | 7.53x | 4.73x | 5.88x | 4.88x | 2.73x | 2.69x | 8.92x |
| Quick Ratio | 11.13x | 10.47x | 7.53x | 4.73x | 5.88x | 4.88x | 2.73x | 2.69x | 8.92x |
| Cash Conversion Cycle | 69.98 | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 63.02M | 79.94M | 74.65M | 95.1M | 41.64M | 53.73M | 92.67M | 156.54M | 73.98M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 263.11M | 68.5M | 74.65M | 78.33M | 13.39M | 14.36M | 14.73M | 17.82M | 393K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 248K | 66K | 100K | 109.08M | 73.59M |
| Total Liabilities | 152.74M | 163.15M | 142.42M | 180.79M | 112.98M | 146.27M | 203.29M | 191.11M | 78.67M |
| Total Debt | 76.6M | 82.25M | 87.76M | 84.67M | 17.34M | 17.96M | 17.99M | 21.19M | 695K |
| Net Debt | -296.77M | -274.76M | -32.49M | -25.29M | -51.06M | -30.01M | -13.01M | -54.82M | -40.56M |
| Debt / Equity | 0.05x | 0.05x | 0.11x | 0.21x | 0.04x | 0.04x | 0.06x | - | - |
| Debt / EBITDA | -0.19x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.75x | - | - | - | - | - | - | - | - |
| Interest Coverage | -1279.94x | -1250.50x | -898.03x | -748.81x | -878.59x | -571.67x | -395.46x | -895.65x | -1340.69x |
| Total Equity | 1.61B | 1.58B | 835.62M | 394.97M | 490.15M | 459.64M | 283.89M | -74.41M | -34.44M |
| Equity Growth % | 310.84% | 89.04% | 111.56% | -19.42% | 6.64% | 61.91% | 481.54% | -116.07% | - |
| Book Value per Share | 16.13 | 18.72 | 11.14 | 6.77 | 9.09 | 9.58 | 6.37 | -1.67 | -0.77 |
| Total Shareholders' Equity | 1.61B | 1.58B | 835.62M | 394.97M | 490.15M | 459.64M | 283.89M | -74.41M | -34.44M |
| Common Stock | 9K | 8K | 7K | 6K | 6K | 5K | 4K | 0 | 0 |
| Retained Earnings | -1.33B | -1.07B | -754.61M | -530.75M | -383.79M | -228.98M | -128.76M | -76.46M | -35.21M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -14.73M | 1.8M | -1.49M | -552K | -4.95M | -660K | -128K | 6K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying KYMR stock.
As of 2025, Kymera Therapeutics, Inc. (KYMR) had total assets of $1.74B including $871.2M in current assets.
Kymera Therapeutics, Inc. (KYMR) carries total debt of $82.3M, offset by $848.3M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Kymera Therapeutics, Inc. (KYMR) has total shareholders' equity (book value) of $1.58B ($18.72 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Kymera Therapeutics, Inc. (KYMR) reported a current ratio of 10.47x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Cash runway tied to financing
Metrics are mathematically derived from official filings.
Equity Base Rebuilt Through Capital Raises
Based on KYMR's reported figures, total equity climbed from about $685M in 2024Q2 to roughly $1.6B in 2026Q3, a rise that appears driven by external capital rather than retained operating earnings given the deepening accumulated deficit.
Retained earnings moved from -$621M to -$1.3B over the same ten quarters, so the equity expansion reflects new paid-in capital absorbing a steady stream of losses. This suggests the balance sheet is strengthening in headline terms while the underlying earnings base continues to erode. Investors should monitor whether future equity additions keep pace with the burn rate.
Cash Buffer Swings With Financing Timing
According to reported balance sheet data, KYMR's cash position moved from $67.6M in 2024Q2 to $373.4M in 2026Q3, with a current ratio consistently above 7x, which on its face indicates ample near-term liquidity.
The lumpy quarter-to-quarter cash levels, such as the drop to $124.5M in 2026Q2 followed by a rebound, appear to reflect the timing of financing inflows relative to quarterly cash burn of roughly $60M to $130M in net losses. A current ratio this high is largely a function of the low liability base, not operating strength. The relevant question is how many quarters the current cash balance covers at the latest burn rate, which warrants further investigation.
Minimal Leverage Keeps Balance Sheet Flexible
Based on reported figures, KYMR's total debt has held between $76M and $88M across the period while the debt-to-equity ratio fell from 0.13 to 0.05, indicating leverage has been diluted by equity growth rather than reduced through repayment.
Because debt has been essentially flat in dollar terms, the improvement in D/E reflects the expanding equity denominator rather than deleveraging. The modest debt load does not appear to create near-term refinancing pressure, but it still carries fixed obligations against a business with no recurring product cash flow. Total liabilities of $130M to $163M suggest limited additional claims beyond the stated debt.
Asset Base Is Cash and Intangible-Light
As reported in financial statements, KYMR carries zero goodwill across all ten quarters and net PP&E of roughly $79M to $100M, placing the asset mix firmly in cash and productive capital rather than acquisition-driven intangibles.
The absence of goodwill removes impairment risk that often distorts biotech balance sheets after acquisitions, making reported asset values more directly tied to cash and facilities. The steady decline in net PP&E from $100.4M to $78.7M appears to reflect depreciation outpacing new capital expenditure. Asset quality is therefore relatively clean, though the value of the asset base depends on the success of the research pipeline rather than on any hard operating assets.
Deferred Revenue Masks Limited Recurring Income
Based on KYMR's reported figures, deferred revenue fell from $22.4M in 2024Q2 to zero by 2026Q3, which may indicate that collaboration prepayments have been fully recognized rather than replenished.
A balance sheet showing no deferred revenue in the latest periods means the forward-visibility cushion from upfront partner payments has largely disappeared. Headline liquidity therefore rests almost entirely on equity and debt funding instead of contracted future receipts. This distortion matters because the strong current ratio can overstate financial resilience if no new collaboration prepayments arrive.